Jim Murray: A surprising development in the case of InterMune vs the EMA

InterMune has withdrawn part of its legal challenge to stop the European Medicines Agency from disclosing certain documents, which relate to the medicine Esbriet (Pirfenidone). The company is still looking for a prohibition on disclosure, but has withdrawn its application for an interim order, which would prevent disclosure before the full hearing of the case. (InterMune […]

Read More…

Muir Gray: Population health—what’s in a name

Suddenly the word population is everywhere. The Oxford University Department of Public Health is now the Department of Population Health Sciences, the Institute for Healthcare Improvement has added population health to form its triple aim, the American Hospital Association talks about a second wave of hospitals with population health as their theme. Furthermore, Public Health […]

Read More…

Desmond O’Neill: Some illuminations on caring for older people

Gothenburg is a handsome city with imposing stone and brick buildings, simultaneously sober and ornamented, set among green hills falling to not one but two archipelagos. It was particularly striking during the unseasonably fine weather that greeted the 22nd Nordic Gerontology Congress last week. This leading regional gerontology conference in Europe is biannual, broad in […]

Read More…

Jim Murray: Policy making behind closed doors

Campaigning for transparency on clinical trial results at EU level is getting to be like playing snakes and ladders, and I’ve just spotted three snakes. I’ve been trying to “deconstruct” the EMA’s reply by letter to the Ombudsman’s concerns about the agency’s volte-face on transparency. The results worry me—a lot. The EMA says that the […]

Read More…